Weill Medical College Of Cornell University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1865-01-01

Employees: -

Market Cap: -

Website: http://weill.cornell.edu

Clinical Trials

Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC
Radiation: Stereotactic Body Radiation Therapy (SBRT)

First Posted Date: 2020-05-26

Last Posted Date: 2025-02-27

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 50

Registration Number: NCT04402151

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
Weill Cornell Medicine, New York, New York, United States

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Phase 2

Active, not recruiting

Conditions: Hematologic Malignancy
Bone Marrow Transplant

Interventions: Drug: Tocilizumab
Drug: Fludarabine
Drug: Melphalan
Drug: Anti-thymocyte globulin (rabbit)
Radiation: Total Body Irradiation

First Posted Date: 2020-05-20

Last Posted Date: 2024-08-19

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 21

Registration Number: NCT04395222

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

A Prospective Trial on Nerve Sparing Techniques Performed in Radical Prostatectomy

Not Applicable

Terminated

Conditions: Prostate Cancer
Quality of Life

Interventions: Procedure: Retzius sparing

First Posted Date: 2020-05-19

Last Posted Date: 2022-03-11

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 3

Registration Number: NCT04393831

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Benefit of Topical Hemostatic Powder Containing Hydrophilic Polymer With Potassium Ferrate for Hemostasis Following Nail Surgery

Phase 4

Withdrawn

Conditions: Nail Diseases

Interventions: Device: Hydrophilic polymer and potassium ferrate powder

First Posted Date: 2020-05-12

Last Posted Date: 2022-08-23

Lead Sponsor: Weill Medical College of Cornell University

Registration Number: NCT04384679

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Radiation: 600cGY x 5 fractions

First Posted Date: 2020-05-01

Last Posted Date: 2025-02-20

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 60

Registration Number: NCT04371913

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
New York Presbyterian Hospital - Queens, New York, New York, United States
🇺🇸
New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States

Case Studies: Promoting Strategy Use in Functional Activities

Not Applicable

Completed

Conditions: Executive Dysfunction
Acquired Brain Injury
Cognitive Impairment

Interventions: Other: Multicontext (MC) approach

First Posted Date: 2020-04-27

Last Posted Date: 2020-04-27

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 8

Registration Number: NCT04363645

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache

Phase 1

Withdrawn

Conditions: Chronic Migraine
Cluster Headache
Trigeminal Neuralgia

Interventions: Drug: Ketorolac
Drug: Dexamethasone

First Posted Date: 2020-04-20

Last Posted Date: 2020-08-04

Lead Sponsor: Weill Medical College of Cornell University

Registration Number: NCT04353505

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

After Cesarean Time Interval for Exercise (ACTIVE) Trial

Not Applicable

Active, not recruiting

Conditions: Postoperative Complications

Interventions: Behavioral: Structured exercise

First Posted Date: 2020-04-14

Last Posted Date: 2024-07-24

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 200

Registration Number: NCT04345757

Locations: 🇺🇸
New York Presbyterian Hospital Weill Cornell, New York, New York, United States

Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma

Phase 1

Active, not recruiting

Conditions: Glioma

Interventions: Drug: 18F-FMISO PET
Drug: 18F-FLT PET

First Posted Date: 2020-03-16

Last Posted Date: 2025-01-29

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 30

Registration Number: NCT04309552

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Phase 2

Active, not recruiting

Conditions: Relapse Multiple Myeloma
Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Drug: Daratumumab SC
Drug: Clarithromycin
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2020-03-10

Last Posted Date: 2025-05-25

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 9

Registration Number: NCT04302324

Locations: 🇺🇸
Weill Cornell Medicine - Multiple Myeloma Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy